DK2819682T3 - Topikale geler indeholdende alpha-connexin c-terminal (act) -peptider - Google Patents
Topikale geler indeholdende alpha-connexin c-terminal (act) -peptider Download PDFInfo
- Publication number
- DK2819682T3 DK2819682T3 DK13755720.3T DK13755720T DK2819682T3 DK 2819682 T3 DK2819682 T3 DK 2819682T3 DK 13755720 T DK13755720 T DK 13755720T DK 2819682 T3 DK2819682 T3 DK 2819682T3
- Authority
- DK
- Denmark
- Prior art keywords
- arg
- ser
- lys
- leu
- topical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Claims (22)
1. Topikal formulering omfattende mindst et alpha-connexin-polypeptid og hydroxyethylcellulosegel, hvor hydroxyethylcellulosegelen stabiliserer alpha-connexin-polypeptidet.
2. Den topikale formulering ifølge krav 1, hvor hydroxyethylcellulosegelen stabiliserer alpha-connexin-polypeptidet, således at efter 3 måneders lagring ved 5 °C, da er mindst 98 % af alpha-connexin-polypeptidet detekterbart med analytiske fremgangsmåder.
3. Den topikale formulering ifølge krav 1, hvor hydroxyethylcellulosegelen stabiliserer alpha-connexin-polypeptidet, således at efter 3 måneders lagring ved 5 °C, da er mindst 95 % af alpha-connexin-polypeptidet detekterbart med analytiske fremgangsmåder.
4. Den topikale formulering ifølge krav 1, hvor hydroxyethylcellulosen er til stede i en koncentration på omkring 1,25 vægtprocent.
5. Den topikale formulering ifølge krav 1, hvor det mindst ene alpha-connexin-polypeptid er til stede i en koncentration på mellem omkring 0,005 vægtprocent og omkring 1,00 vægtprocent.
6. Den topikale formulering ifølge krav 1, yderligere omfattende et buffermiddel, der opretholder pH'en af den topikale formulering mellem omkring 5 og omkring 7.
7. Den topikale formulering ifølge krav 6, hvor buffermidlet er en phosphatbuffer.
8. Den topikale formulering ifølge krav 1, hvor det mindst ene alpha-connexin-polypeptid omfatter de mest carboxy-terminale 4 til 30 sammenhængende aminosyrer af et alpha-connexin-protein eller konservativ variant deraf.
9. Den topikale formulering ifølge krav 8, hvor det mindst ene alpha-connexin-polypeptid er forbundet ved sin aminoterminus til en cellulær internaliseringstransporter.
10. Den topikale formulering ifølge krav 9, hvor den cellulære internaliseringstransporter er en antennapedia-sekvens.
11. Den topikale formulering ifølge krav 8, hvor det mindst ene alpha-connexin-polypeptid omfatter aminosyresekvensen af SEQ ID NO: 9.
12. Den topikale formulering ifølge krav 8, hvor alpha-connexin-polypeptidet er connexin 37, connexin 40, connexin 43 eller connexin 45.
13. Den topikale formulering ifølge et hvilket som helst af kravene 1-12, til anvendelsen i en fremgangsmåde til sårbehandling.
14. Den topikale formulering ifølge krav 13 til anvendelsen ifølge krav 13, hvor såret er et akut kirurgisk sår.
15. Den topikale formulering ifølge krav 13 til anvendelsen ifølge krav 13, hvor såret er et kronisk sår.
16. Den topikale formulering ifølge krav 13 til anvendelsen ifølge krav 13, hvor såret er et kronisk, ikke-inficeret, fuldtykkelse åbent sår i de nedre ekstremiteter.
17. Den topikale formulering ifølge krav 13 til anvendelsen ifølge krav 13, hvor såret er et venøst bensår.
18. Den topikale formulering ifølge krav 13 til anvendelsen ifølge krav 13, hvor såret er et diabetisk fodsår.
19. Den topikale formulering ifølge krav 13 til anvendelsen ifølge krav 13, hvor såret er et tryksår.
20. Den topikale formulering ifølge krav 13 til anvendelsen ifølge krav 13, hvor lægemidlet administreres til individet i en doseringsplan ved dag 0, dag 3, dag 7, dag 14, dag 21 og dag 28.
21. Den topikale formulering ifølge krav 13 til anvendelsen ifølge krav 13, hvor lægemidlet er administreret til individet i en doseringsplan ved dag 0, dag 3, uge 1, uge 2, uge 3, uge 4, uge 5, uge 6, uge 7, uge 8, uge 9, uge 10, uge 11 og uge 12.
22. Fremgangsmåde til fremstilling af en topikal formulering omfattende: a) at blande propylenglycol, glycerin, methylparaben og propylparaben, indtil parabenerne er fuldkommen opløst; b) separat at blande renset vand, EDTA, monobasisk natriumphosphat, dibasisk natriumphosphat og D-mannitol, indtil en klar opløsning opnås; c) at tilsætte opløsningen fra a) til opløsningen fra b), at vaske beholderen af opløsningen fra a) med renset vand, at tilsætte vaskemediet til de kombinerede opløsninger, og at blande indtil de kombinerede opløsninger er visuelt homogene; d) med homogeniseringsblanding, at tilsætte hydroxyethylcellulose til de kombinerede opløsninger af c) og at blande indtil polymeren er fuldkommen dispergeret; e) separat at blande renset vand med et alpha-connexin-polypeptid indtil peptidet er fuldkommen opløst; f) at tilsætte opløsningen fra e) til opløsningen af d), at vaske beholderen af opløsningen fra e) med renset vand, at tilsætte vaskemediet til de kombinerede opløsninger, og at blande indtil de kombinerede opløsninger er homogene.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261605528P | 2012-03-01 | 2012-03-01 | |
PCT/US2013/028727 WO2013131040A1 (en) | 2012-03-01 | 2013-03-01 | Topical gels containing alpha connexin c-terminal (act) peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2819682T3 true DK2819682T3 (da) | 2017-08-21 |
Family
ID=49083360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13755720.3T DK2819682T3 (da) | 2012-03-01 | 2013-03-01 | Topikale geler indeholdende alpha-connexin c-terminal (act) -peptider |
Country Status (18)
Country | Link |
---|---|
US (5) | US8846605B2 (da) |
EP (1) | EP2819682B1 (da) |
JP (1) | JP6185937B2 (da) |
KR (1) | KR102038948B1 (da) |
CN (1) | CN104271142B (da) |
AU (1) | AU2013225716B2 (da) |
BR (1) | BR112014021653B1 (da) |
CA (1) | CA2866115C (da) |
DK (1) | DK2819682T3 (da) |
HK (1) | HK1205451A1 (da) |
IL (1) | IL234380B (da) |
IN (1) | IN2014DN07420A (da) |
MX (1) | MX351881B (da) |
NZ (1) | NZ629769A (da) |
RU (1) | RU2657535C2 (da) |
SG (1) | SG11201405359YA (da) |
WO (1) | WO2013131040A1 (da) |
ZA (1) | ZA201406373B (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5548121B2 (ja) | 2007-05-14 | 2014-07-16 | リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク | バイオフィルム中の細菌細胞における生理学的分散応答の誘導 |
MX351881B (es) | 2012-03-01 | 2017-11-01 | Firststring Res Inc | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
US11246821B2 (en) * | 2016-08-30 | 2022-02-15 | Rohm And Haas Company | Personal care composition |
WO2018151823A1 (en) * | 2017-02-16 | 2018-08-23 | Firststring Research, Inc. | Composition and methods for preventing radiation injury and promoting tissue regeneration |
JP6901801B2 (ja) * | 2017-06-14 | 2021-07-14 | バイオソリューション カンパニー・リミテッドBio Solution Co Ltd | 物質pを含むしわの改善または抗炎症化粧料組成物 |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
BR112021004731A2 (pt) * | 2018-09-12 | 2021-09-08 | Firststring Research, Inc. | Formulações de nanopartículas e métodos de uso para peptídeos de terminal-c alfa conexina. |
RU2691647C1 (ru) * | 2018-11-29 | 2019-06-17 | Артем Иванович Трофименко | Средство для профилактики образования патологических кожных рубцов |
US11751056B2 (en) * | 2020-08-31 | 2023-09-05 | Oracle International Corporation | Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns |
WO2023212446A1 (en) * | 2022-04-29 | 2023-11-02 | Xequel Bio, Inc. | Compositions and methods for treating complications of viral infections and other respiratory disorders |
CN117582401B (zh) * | 2023-12-07 | 2024-04-26 | 唐宁医药科技(济南)有限公司 | 一种糖尿病足凝胶及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3603444A1 (de) | 1986-02-05 | 1987-08-06 | Thomae Gmbh Dr K | Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha |
NZ222413A (en) | 1986-11-05 | 1991-06-25 | Ethicon Inc | Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser |
US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
CA2080538A1 (en) * | 1991-10-21 | 1993-04-22 | Joseph V. Bondi | Lyophilized acidic fibroblast growth factor |
US5401504B1 (en) * | 1993-12-28 | 1998-04-21 | Univ Mississippi Medical Cente | Use of tumeric in wound healing |
ES2498745T3 (es) | 1999-01-27 | 2014-09-25 | Coda Therapeutics, Inc. | Formulaciones que comprenden nucleótidos antisentido para conexinas |
WO2000069896A2 (en) | 1999-05-14 | 2000-11-23 | Arbor Vita Corporation | Molecular interactions in haematopoietic cells |
US7250397B2 (en) | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
WO2002042422A2 (en) | 2000-11-10 | 2002-05-30 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
WO2002088370A2 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Autogene nucleic acids encoding a secretable rna polymerase |
US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
US6685971B2 (en) | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
CN1827766B (zh) | 2001-06-28 | 2010-08-25 | 徐荣祥 | 体外细胞的培养方法 |
EP1443951A4 (en) | 2001-08-03 | 2006-05-03 | Arbor Vita Corp | MOLECULAR INTERACTIONS IN CELLS |
JP2005509621A (ja) | 2001-10-17 | 2005-04-14 | ユニバーシティ オブ ウェールズ カレッジ オブ メディスン | ギャップ結合ならびにedhf |
JP2003238441A (ja) | 2002-02-08 | 2003-08-27 | 英行 ▲高▼野 | 血管新生抑制剤 |
AU2003234613A1 (en) | 2002-05-15 | 2003-12-02 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
IL152573A (en) * | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
DK1699924T3 (da) | 2003-12-03 | 2019-10-21 | Ocunexus Therapeutics Inc | Connexin 43-målrettede hæmmende forbindelser og fremgangsmåder til anvendelse deraf i behandling af hornhindetraume |
US7786074B2 (en) | 2004-12-21 | 2010-08-31 | MUSC Foundation for Research Development Charleston | Composition and methods for promoting wound healing and tissue regeneration |
CN101151043B (zh) * | 2004-12-21 | 2013-09-04 | 南卡罗来纳州医科大学研究发展基金会 | 促进伤口愈合和组织再生的组合物和方法 |
CA2596412A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
CA2612405A1 (en) * | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage |
CN101198346A (zh) * | 2005-06-17 | 2008-06-11 | 雷金纳克斯生物制药公司 | Lkktet和/或lkktnt肽组合物及方法 |
WO2007044487A1 (en) * | 2005-10-11 | 2007-04-19 | Dfb Pharmaceuticals, Inc. | Surfactant-free dispersions, compositions, and use in topical formulations |
GB0709513D0 (en) * | 2007-05-17 | 2007-06-27 | Helperby Therapeutics Ltd | Topical formulations |
WO2008060622A2 (en) | 2006-11-15 | 2008-05-22 | Coda Therapeutics, Inc. | Improved methods and compositions for wound healing |
EP2543378A1 (en) | 2006-12-11 | 2013-01-09 | Coda Therapeutics, INC. | Anticonnexin polynucleotides as impaired wound healing compositions |
US20080299228A1 (en) * | 2007-05-29 | 2008-12-04 | Alan Gerald Harris | Topical compositions comprising a macromolecule and methods of using same |
US20110130345A1 (en) | 2007-06-21 | 2011-06-02 | Baerbel Rohrer | Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration |
CA2592285C (en) | 2007-06-28 | 2019-10-01 | Musc Foundation For Research Development | Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides |
CN102105492A (zh) * | 2007-12-11 | 2011-06-22 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
US20100279921A1 (en) | 2007-12-11 | 2010-11-04 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
JP2011507856A (ja) | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用 |
EP2252689A2 (en) | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
AU2008343842A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions |
US20110130710A1 (en) | 2007-12-21 | 2011-06-02 | David Lawrence Becker | Treatment of abnormal or excessive scars |
CA2710387A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of fibrotic conditions |
JP2011507599A (ja) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 改良医療デバイス |
AU2008343841A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of connexin43 for treatment of fibrotic conditions |
AU2008343839A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions |
WO2009085274A2 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars |
CA2711635A1 (en) * | 2008-01-07 | 2009-08-06 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
JP2011524345A (ja) | 2008-06-04 | 2011-09-01 | コーダ セラピューティクス, インコーポレイテッド | ギャップジャンクション調節化合物を用いる疼痛の治療 |
MX351881B (es) | 2012-03-01 | 2017-11-01 | Firststring Res Inc | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
-
2013
- 2013-03-01 MX MX2014010501A patent/MX351881B/es active IP Right Grant
- 2013-03-01 CN CN201380023492.XA patent/CN104271142B/zh active Active
- 2013-03-01 AU AU2013225716A patent/AU2013225716B2/en active Active
- 2013-03-01 JP JP2014560104A patent/JP6185937B2/ja active Active
- 2013-03-01 KR KR1020147027397A patent/KR102038948B1/ko active IP Right Grant
- 2013-03-01 DK DK13755720.3T patent/DK2819682T3/da active
- 2013-03-01 WO PCT/US2013/028727 patent/WO2013131040A1/en active Application Filing
- 2013-03-01 CA CA2866115A patent/CA2866115C/en active Active
- 2013-03-01 SG SG11201405359YA patent/SG11201405359YA/en unknown
- 2013-03-01 BR BR112014021653-3A patent/BR112014021653B1/pt active IP Right Grant
- 2013-03-01 NZ NZ629769A patent/NZ629769A/en unknown
- 2013-03-01 RU RU2014139668A patent/RU2657535C2/ru active
- 2013-03-01 EP EP13755720.3A patent/EP2819682B1/en active Active
- 2013-03-15 US US13/815,723 patent/US8846605B2/en active Active
-
2014
- 2014-07-25 US US14/341,406 patent/US9161984B2/en active Active
- 2014-08-29 ZA ZA2014/06373A patent/ZA201406373B/en unknown
- 2014-08-31 IL IL234380A patent/IL234380B/en active IP Right Grant
- 2014-09-03 IN IN7420DEN2014 patent/IN2014DN07420A/en unknown
-
2015
- 2015-06-19 HK HK15105846.8A patent/HK1205451A1/xx unknown
- 2015-09-09 US US14/848,916 patent/US10632173B2/en active Active
-
2020
- 2020-04-27 US US16/859,075 patent/US11524049B2/en active Active
-
2022
- 2022-10-06 US US17/938,624 patent/US20230263857A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2819682T3 (da) | Topikale geler indeholdende alpha-connexin c-terminal (act) -peptider | |
US10478394B2 (en) | Compositions and methods to promote wound healing | |
JP2017226665A (ja) | 1型糖尿病の治療における使用のためのfgf21 | |
ES2236010T3 (es) | Composiciones de polipeptidos con estabilidad mejorada. | |
CA2832581C (en) | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) | |
ES2970509T3 (es) | Composición y métodos para prevenir lesión por radiación y fomentar la regeneración tisular | |
CN104080473A (zh) | 包含胰岛素氨基酸序列的治疗剂 | |
KR20080031405A (ko) | 상피 재생의 촉진 | |
EP3294312B1 (en) | Materials for tissue regeneration | |
CN112368295A (zh) | 离子性自组装肽 | |
US20240051997A1 (en) | Sap and peptidomimetic compositions for reducing symptoms of inflammation | |
US20200000890A1 (en) | Use of apc analogue for wound healing | |
TW201204384A (en) | Lactoferrin sequences, compositions and methods of wound treatment | |
RU2772456C2 (ru) | Композиции и способы для предотвращения радиационного поражения и стимуляции регенерации ткани | |
CA3196342A1 (en) | Peptide formulations and ophthalmic uses thereof |